

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number				09/785,235	
Filing Date				February 20, 2001	
First Named Inventor				Francis GILES et al.	
Group Art Unit				Not Yet Assigned	
Examiner Name				Not Yet Assigned	
Attorney Docket Number				PHARMA 115	


[illegible][illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	12-23-03
-----------------------	--------------------	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	09/785,235
Filing Date	February 20, 2001
First Named Inventor	Francis GILES et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PHARMA 115

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PL		Tai Shun et al., "Synthesis and Anticancer Activity of Various 3'-Deoxy Pyrimidine Nucleoside Analogues and Crystal Structure of 1-(3-Deoxy-b-D-threo-pentofuranosyl) cytosine	
		Mineo Saneyoshi et al., "Synthetic Nucleosides and Nucleotides. XXXV. Synthesis and Biological Evaluations of 5-Fluoropyrimidine Nucleosides and Nucleotides of 3-Deoxy-β-D-ribofuranose and Related Compounds	
		Janos Ludwig and Fritz Eckstein, "Rapid and Efficient Synthesis of Nucleoside 5'-O-(1-Thiotriphosphates), 5'-Triphosphates and 2',3'-Cyclophosphorothioates Using 2-Chloro-4H-1,3,2-benzodioxaphosphorin-4-one", J. Org. Chem. 1989, 54, 631-635	
		Stephen Hanessian and Pierre Lavellée, "The Preparation and Synthetic Utility of tert-Butyldiphenisilyl Ethers", Can. J. Chem. 1975, 53(19), 2975-2977	
		Stephen H. Kawai et al., "Synthesis of Branched-China And Bicyclic Thiosugar Nucleosides" from Nucleosides Nucleotides, edited by Leroy B. Townsend, 1988 Plenum Press Volumes 1 and 2, 1990, 9(8), 1045-1060	
		Krzysztof W. Pankiewicz et al., J. Org. Chem. 1992, 57, 7315-7321, Synthesis of 2'-β-Fluoro- and 3'-α-Fluoro-Substituted Guanine Nucleosides. Effects of Sugar Conformational Shifts on Nucleophilic Displacement of the 2'-Hydroxy and 3'-Hydroxy Group with DAST	
		Igor A. Mikhailopulo et al., J. Med. Chem. 1991, 34, 2195-2202, Synthesis and Antiviral and Cytostatic Properties of 3'-Deoxy-3'-Deoxy-3'-fluoro- and 2'-Azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of Natural Heterocyclic Bases	
		Frédéric Puech et al., Chem. Commun. 1989, (14), 955-957, Synthesis of 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-guanine, a New Potent Antiviral Agent	
		Van Aerschot et al., Antiviral Research, 12, 1989, 133-150, Synthesis and antiviral activity evaluation of 3'-fluoro-3'-deoxyribonucleosides: broad-spectrum antiviral activity of 3'-fluoro-3'-deoxyadenosine	
		Igor A. Mikhailopulo et al., FEBS Lett. 1989, 250(2), 139-141, 3'-Fluoro-3'-deoxyribonucleoside 5'-triphosphates: synthesis and use as terminators of RNA biosynthesis	
		Hemant K. Misra et al., J. Heterocycl. Chem., May-June 1984, 21(3), 773-775, Reaction of 1-(2,3-Epoxy-β-D-lyxofuranosyl)uracil with Hydrogen Fluoride. The Unexpected Formation of 1-(3'-Fluoro-3'-deoxy-β-ribofuranosyl)-uracil	

Examiner
Signature

[Signature]


Date
Considered

12-23-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	09/785,235
Filing Date	February 20, 2001
First Named Inventor	Francis GILES et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PHARMA 115

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PL		G. Kowolik et al, J. Carbohydr., Nucleosides, Nucleotides, 1975, 2(3), 191-195, Nucleosides of Fluorocarbohydrates, XIII synthesis of 3'-deoxy-3'-fluorouridine	
		Tokumi Maruyama et al., Nucleic Acids Symp. Ser. 1997, 37, 17-18, Synthesis of the 2'-deoxy-2'-fluoro and 3'-deoxy-3'-fluoro analogues of 8-nomoadenosine	
		Tokumi Maruyama et al., Nucleosides & Nucleotides 1998, 17(1-3), 115-122, Synthesis of 8-substituted analogus of 3'-deoxy-3'-fluoradenosine	
		Giordani et al., Nucleosides & Nucleotides 1991, 10(1-3), 719-721, A New Synthesis of 3'-Fluoro-3'-deoxyadenosine	
		Carlo Battistini et al., Synthesis, 1990, (10), 900-905, Synthesis of 3'-Fluoro-3'-deoxyadenosine Starting from Adenosine	
		Andrea Neumann et al., Z. Chem., 1989, 29(6), 209-210, Über die Synthese von 3'-desoxy-3'-fluoradenosin dureh chemische Transglykosidierung	
		Yoshitomi Morizawa et al., Bull. Chem. Soc. Jpn., June 1989, 62(6), 2119-2120, Stereoselective Synthesis of 3'-Deoxy-3'-fluoradenosine	
		P. Herdewijn et al., Nucleosides & Nucleotides, 1989, 8(1), 65-96, Synthesis of Nucleosides Fluorinated in the Sugar Moiety. The Application of Diethylaminosulfur Trifluoride to the Synthesis of Fluorinated Nucleosides	
		Elzbieta Lewandowska et al., Tetrahedron, 1997, 53(18), 6295-6302, Efficient Removal of Sugar A-Tosyl Groups and Heterocycle Halogens from Purine Nucleosides with Sodium Haphthalenide	
		P. Herdewijn et al., J. Med. Chem., 1987, 30(11), 2131-2137, P. Herdewijn et al., Synthesis and Anti-HIV Activity of Various 2'-and 3'-Substituted 2',3'-Dideoxyadenosines: A Structure-activity Analysis	
		V.I. Kobinskaya et al., Bioorg. Khim., 1994, 20(11), 1226-1230, Synthesis of Fluoro and Aido Derivatives of Purine Nucleosides from Nucleosides 2',3'-Cyclosulphates	
		Piet Herdewijn et al., Helvetica Chim. Acta, 1991, 74(1), 7-23, Synthesis of Modified Oligomeric 2'-5' A Analogues: Potential Antiviral Agents	
		Hiroyuki Hayakawa et al., Chem. Pharm. Bull., 1990, 38(5), 1136-1139, Diethylaminosulfur (DAST) as a Fluorinating Agent of Pyrimidine Nucleosides Having a 2',3'-Vicinal Diol System	
		Frédéric Puech et al., Tetrahedron Lett., 1990, 30(24), 3171-3174, Synthesis of 9-(3-Deoxy-and 2,3-Dideoxy-3-Fluoro-β-D-Xylofuranosyl) Guanines as Potential Antiviral Agents	
✓		Morris J. Robins et al., J. Org. Chem., 1974, 39(11), 1564-1570, Nucleic Acid Related Compounds. 11. Adenosine 2',3'-ribo-Epoxide. Synthesis, Intramolecular Degradation, and Transformation into 3'-Substituted Xylofuranosyl Nucleosides and the lyxo-Epoxidol	

Examiner
Signature

[Signature]


Date
Considered

12-23-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	09/785,235
Filing Date	February 20, 2001
First Named Inventor	Francis GILES et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PHARMA 115

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PL		John A. Wright et al., J. Med. Chem., 1970, 13(2), 269-272, Nucleosides. LXIV. Fluoro Sugar Analogs of Arabinosyl- and Xylofuranosyls	
		J.A. Wright et al., Carbohydr. Res., 1968, 6(3), 347-54, Fluorocarbohydrates Part XVIII. 9-(3-Deoxy-3-Fluoro-β-D-Xylofuranosyl) Adenine and 9-(3-Deoxy-3-Fluoro-α-D-Arabinofuranosyl) Adenine	
		Donald E. Bergstrom et al., J. Med. Chem., 1992, 35(18), 3369-3372, 3',3'-Difluoro-3'-deoxythymidine: Comparison of Anti-HIV Activity to 3'-Fluoro-3'-deoxythymidine	
		Vincente Samano et al., Tetrahedron Lett., 1994, 35(21), 3445-3448, Synthesis of 3'-Deoxyadenosine-3'Spirocyclopropane, 3'-Deoxy-Uridine-3'-Spirocyclopropane, and 5'-Deoxy-4',5'-Methanoadenosine	
		Panagiotis Ioannidis et al., Nucleosides & Nucleotides, 1993, 12(8), 865-877, Synthesis of 2',3'-Dideoxy-2',3'-Dideoxy-3'-C-Methyl Substituted Nucleosides	
		Vincente Samano et al., Can. J. Chem., 1993, 71(2), 1868-191, Nucleic acid related compounds. 77. 2',3'-Dideoxy-2',3'-dideoxy-2'(and 3')-methyl nucleosides via [3,3]-sigmatropic rearrangements of 2'(and 3')-methylene-3'(and 2')-O-thiocarbonyl derivatives and radical reduction of a 2'-chloro-3'-methylene analogue	
		Morris J. Robins et al., J. Med. Chem., 1992, 35(12), 2283-2293, Nucleic Acid Related Compounds. 74. Synthesis and Biological Activity of 2'(and 3')-Deoxy-2'(and 3')-methylene nucleoside Analogues That Function as Mechanism-Based Inhibitors of S-Adenyl-L-homocysteine Hydrolase and/or Ribonucleotide Reductase	
		Tai-Shun Lin et al., J. Med. Chem., 1991, 34(8), 2607-2615, Synthesis and Anticancer and Antiviral Activities of Various 2'- and 3'-Methylidene-Substituted Nucleoside Analogues and Crystal Structure of 2'-Deoxy-2'-methylidene cytidine Hydrochloride	
		Vincente Samano et al., Synthesis, 1991, (4), 283-288, Stereoselective Addition of a Wittig Reagent To Give A Single Nucleoside Oxaphosphetane Diastereoisomer. Synthesis of 2'(and 3')-methyleneuridine (and cytidine) Derivatives from Uridine Ketonucleosides	
		Jean M.J. Trochet et al., Helvetica, Chim. Acta, 1981, 64(2), 425-429, 42. Un nouvel exemple de nucléoside à sucre ramifié insaturé: la désoxy-3'-méthylidène-3'-adénosine	
✓		Vincente Samano et al., J. Org. Chem., 1991, 56(25), 7108-7113, Nucleic Acid Related Compounds. 70. Synthesis of 2'(and 3')-Deoxy-2'(and 3')-methyleneadenosines and Bis (methylene)furan 4',5'-Dideoxy-5'-deoxy-2'(and 3')-methyleneadenosines. Inhibitors of S-Adenyl-L-homocysteine Hydrolase and Ribonucleotide Reductase	

Examiner
Signature

[Signature]

Date


Considered

12-23-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Complete if Known

Application Number	09/785,235
Filing Date	February 20, 2001
First Named Inventor	Francis GILES et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PHARMA 115

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PK		Akira Matsuda et al., Nucleosides & Nucleotides, 1992, 11(2-4), 197-226, Nucleosides and Nucleotides. 104. Radical and Palladium-Catalyzed Deoxygenation of the Allylic Alcohol Systems in the Sugar Moiety of Pyrimidine Nucleosides	
		Pawel J. Serafinowski et al., Nucleosides & Nucleotides, 1997, 16(7-9), 1529-1532, Synthesis and NMR Spectra of some new Carbohydrate modified Uridine Phosphoramidites	
		Pawel J. Serafinowski et al, Tetrahedron, 1996, 52 (23), 7929-7938, New Method for the Preparation of 3'- and 2'-Phosphoramidites of 2'- and 3'-Difluoromethyleneuridine	
		Sven-Erik Behrens et al., EMBO 15, 1996, 12-22, Identification and properties of the RNA-dependent RNA polymerase of hepatitis C Virus	
		Volker Lohmann et al., J. Virol., 1997, 71, 8416-8428, Biochemical Properties of Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase and Identification of Amino Acid Sequence Motifs Essential for Enzymatic Activity	
		Vladimir D. Axelrod et al., Biochemistry, 1985, 24, 5716-5723, Transcription from Bacteriophage T7 and SP6 RNA Polymerase Promoters in the Presence of 3'-Deoxyribonucleoside 5'-Triphosphate Chain Terminators	
		Vladimir D. Axelrod et al., Nucleic Acids Research, Volume 5, Number 10, October 1978, 3549-3563, Specific termination of RNA Polymerase Synthesis as a method of RNA and DNA sequencing	
		Gilles Gosselin et al., J. Med. Chem., 1986, 29, 203-213, Systematic Synthesis and Biological Evaluation of α - and β -D-Zylofuranosyl Nucleosides of the Five Naturally Occurring Bases in Nucleic Acids and Related Analogues	
		Satoru Suzuki et al., Molecular Pharmacology, 30, 301-306, A Proposed Mechanism for the Selective Inhibition of Human Cytomegalovirus Replication by 1-(2'-Deoxy-2'-fluoro- β -D-Arabinofuranosyl)-5-fluorouracil	
		J.M. Crance et al., Journal of Medical Virology 31, 1990, 155-160, Inhibition of Hepatitis A Virus Replication In Vitro by Antiviral Compounds	
		Minzo Saneyoshi et al., Chem. Pharm. Bulletin, 30, (6), 1982, 2223-2227, Synthetic Nucleosides and Nucleotides. XIX. Synthesis of 3'-Deoxycytidine 5'-Triphosphate and Related 3'-Deoxy-ribonucleotides from Cordycepin	

Examiner
Signature

Date
Considered

12-23-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet	6	of	6
-------	---	----	---

BPH:immK:\PHARMA\115\PTO-1449.dot

+

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/785,235
Filing Date	February 20, 2001
First Named Inventor	Francis GILES et al.
Group Art Unit	1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	PHARMA 115

(use as many sheets as necessary)

Sheet	1	of	2g
-------	---	----	----

[illegible][illegible]

12-23-07

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

OCT 02 2002

TECH CENTER 1600/2900



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Compleat if Known

Application Number	09/785,235
Filing Date	February 20, 2001
First Named Inventor	Francis GILES et al.
Group Art Unit	1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	PHARMA 115

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
1/L	4	RUTSCHMANN et al., "Impact of Treatment with Human Immunodeficiency Virus (HIV) Protease Inhibitors on Hepatitis C Viremia in Patients Coinfected with HIV", <u>The Journal of Infectious Diseases</u> , 1998, pp783-185, Vol. 177	
	5	AHMED et al., "Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference", <u>Journal of Gastroenterology and Hepatology</u> , 1999, pp S12-S18, Vol. 14	
	6	BRILLANTI et al., "Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders", <u>Ital. J. Gastroenterol. Hepatol.</u> , 1999, pp 130-134, Vol 31	
↓	7	EP International Search Report dated June 10, 2002	

Examiner
Signature

Date

Considered

12-23-02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

OCT 02 2002

TECH CENTER 1600/2900